BRIEF—Amarin names new head of UK business to lead growth

Ireland-headquartered fish oil-based heart drug specialist Amarin Corp plans to drive forward the next phase of its commercial expansion with the major new appointment of Scott Curley to its UK and Ireland team as general manager.

This latest appointment comes off the back of receiving a positive recommendation from the UK’s National Institute for Health and Care Excellence (NICE) for Vazkepa (icosapent ethyl), which has given Amarin the green light to pursue significant commercial expansion.

Mr Curley joins the Amarin team from global pharmaceutical giant AstraZeneca.

Prior to this, he held a variety of local and global roles at GlaxoSmithKline and SmithKlineBeecham.